In the spring of 2013, two businessmen from an American subsidiary of an Indian generics manufacturer travelled to Pune to visit their parent company, Emcure Pharmaceuticals. They met Satish Mehta, Emcure’s billionaire chief executive, to discuss the upcoming launch of a drug called Doxy DR.

Doxy DR (doxycycline hyclate delayed-release) is a simple molecule—a delayed-release antibiotic often prescribed for severe acne. The businessmen from New Jersey-based Heritage Pharmaceuticals wanted to manufacture this profitable drug.

The catch: The market was entirely cornered by Heritage’s competitor, Mylan N.V., so its entry had to be carefully orchestrated.

AUTHOR

Gayathri Vaidyanathan

Gayathri writes on health, environment and science. She has reported and produced stories for the Washington Post, Discover, Nature, and the New York Times, amongst other publications. In her last assignment, she was the lead science writer for E&E News in Washington, D.C. E&E News is a news organisation focused on energy and the environment. Over the past decade, Gayathri has travelled across North America, Africa and Asia on long-form reporting projects. She has a master’s in journalism from Columbia University and a bachelor's in biochemistry from McMaster University in Ontario. At The Ken, Gayathri will write on healthcare, the pharmaceutical business and the environment. Based in Bengaluru, you can reach her at gayathri at the rate the-ken.com

View Full Profile

Sign up to our India edition to read this story instantly

To sign up, you’ll create an account that will give you access to a new free story published once a week and archive of 214+ previously published free stories from our India edition. You’ll also receive one email every morning from us introducing the day’s story.

If you’ve already signed up, just enter your email below or login using Facebook or Google.

Or use your email ID